Company news

Adaptive Biotechnologies Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference

August 31, 2020

Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit

August 9, 2020

Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results

August 9, 2020

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia

August 5, 2020

Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2

August 3, 2020

Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease

July 27, 2020

Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock

July 14, 2020

Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock

July 13, 2020

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020

July 8, 2020

UPDATE – Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

June 7, 2020

Adaptive Biotechnologies Reports First Quarter 2020 Financial Results

May 11, 2020

Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference

May 5, 2020

Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020

April 26, 2020

Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx

April 8, 2020

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020

Adaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference

February 18, 2020

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020

February 11, 2020

Adaptive Announces Pricing of Public Offering of Common Stock

January 22, 2020

Adaptive Announces Proposed Public Offering of Common Stock

January 20, 2020

Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019

January 20, 2020

Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

January 12, 2020

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia

January 7, 2020

Adaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference

December 29, 2019

Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

December 8, 2019

Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients

December 3, 2019

Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results

November 11, 2019

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 12, 2019

October 28, 2019

Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx

September 23, 2019

Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise

September 16, 2019

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.